172 related articles for article (PubMed ID: 18756910)
1. Association of CYP2C9 gene polymorphism with bleeding as a complication of warfarin therapy.
Samardzija M; Topić E; Stefanović M; Zibar L; Samardzija G; Balen S; Vcev A; Domanović D; Mirat J; Barbić J
Coll Antropol; 2008 Jun; 32(2):557-64. PubMed ID: 18756910
[TBL] [Abstract][Full Text] [Related]
2. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
5. Genetic modulation of oral anticoagulation with warfarin.
Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
[TBL] [Abstract][Full Text] [Related]
6. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
7. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation].
Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358
[TBL] [Abstract][Full Text] [Related]
8. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
9. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2C9 gene polymorphisms on anticoagulant therapy after heart valve replacement.
Yildirim H; Tamer L; Sucu N; Atik U
Med Princ Pract; 2008; 17(6):464-7. PubMed ID: 18836275
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
Caraco Y; Blotnick S; Muszkat M
Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
[TBL] [Abstract][Full Text] [Related]
12. [The application of thrombin generation tests to warfarin anticoagulation monitoring].
Chen HY; Ding QL; Zhang LW; Xu GQ; Dai J; Wang XF; Xi XD; Wang HL
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):168-70. PubMed ID: 18788615
[TBL] [Abstract][Full Text] [Related]
13. Genetic regulation of warfarin metabolism and response.
Daly AK; Aithal GP
Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
[TBL] [Abstract][Full Text] [Related]
14. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
Lindh JD; Lundgren S; Holm L; Alfredsson L; Rane A
Clin Pharmacol Ther; 2005 Nov; 78(5):540-50. PubMed ID: 16321620
[TBL] [Abstract][Full Text] [Related]
15. The relationship between CYP2C9 gene polymorphisms and upper gastrointestinal bleeding in patients who used warfarin.
Ucar M; Alagozlu H; Sahin S; Ozdemir O
Med Glas (Zenica); 2013 Feb; 10(1):50-4. PubMed ID: 23348161
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
Leey JA; McCabe S; Koch JA; Miles TP
Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
[TBL] [Abstract][Full Text] [Related]
17. [Factors influencing activity of oral anticoagulants. Interactions with drugs and food].
Sawicka-Powierza J; Rogowska-Szadkowska D; Ołtarzewska AM; Chlabicz S
Pol Merkur Lekarski; 2008 May; 24(143):458-62. PubMed ID: 18634396
[TBL] [Abstract][Full Text] [Related]
18. Thrombomodulin as a marker for bleeding complications during warfarin treatment.
Lind M; Boman K; Johansson L; Nilsson TK; Ohlin AK; Birgander LS; Jansson JH
Arch Intern Med; 2009 Jul; 169(13):1210-5. PubMed ID: 19597070
[TBL] [Abstract][Full Text] [Related]
19. Discrepancies in identification of major bleeding events in patients taking warfarin.
Seto AC; Kenyon K; Wittkowsky AK
Pharmacotherapy; 2008 Sep; 28(9):1098-103. PubMed ID: 18752380
[TBL] [Abstract][Full Text] [Related]
20. Bleeding complications from warfarin anticoagulation in patients with malignancy.
Zacharski LR; Henderson WG; Forman WB; Edwards RL; Cornell CJ; Forcier RJ; Headley E; Kim SH; O'Donnell JF; O'Dell R
J Med; 1985; 16(5-6):535-61. PubMed ID: 3913728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
